scholarly journals Recommendations Russian Society of Dermatovenerologists and Cosmetologists for systemic treatment of psoriasis during the pandemic COVID-19

2020 ◽  
Vol 96 (2) ◽  
pp. 9-13
Author(s):  
Alexey A. Kubanov ◽  
Andrey L. Bakulev ◽  
Muza M. Kokhan ◽  
Olga Yu. Olisova ◽  
ALexey V. Samtsov ◽  
...  
Keyword(s):  
Systemic Treatment ◽  
Severe Psoriasis ◽  
Published Data ◽  
Russian Society ◽  
Clinical Recommendations

Below you will find the analysis of the first published data and international clinical recommendations for the systemic treatment of patients with moderate and severe psoriasis in the context of the COVID-19 pandemic in different countries (France, Italy, USA, Spain, and Germany).

scholarly journals IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis

2022 ◽  
Vol 23 (1) ◽  
pp. 555
Author(s):  
Xing Wang ◽  
Hannah Kaiser ◽  
Amanda Kvist-Hansen ◽  
Benjamin D. McCauley ◽  
Lone Skov ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Plasma Proteins ◽  
Systemic Treatment ◽  
Severe Psoriasis ◽  
Atherosclerotic Cardiovascular Disease ◽  
Strong Correlations ◽  
Potential Marker ◽  
Chronic Inflammatory Condition ◽  
Circulating Levels ◽  
Potential Biomarkers

Psoriasis is a chronic inflammatory condition associated with atherosclerotic cardiovascular disease (CVD). Systemic anti-psoriatic treatments mainly include methotrexate and biological therapies targeting TNF, IL-12/23 and IL-17A. We profiled plasma proteins from patients with moderate-to-severe psoriasis to explore potential biomarkers of effective systemic treatment and their relationship to CVD. We found that systemically well-treated patients (PASI < 3.0, n = 36) had lower circulating levels of IL-17 pathway proteins compared to untreated patients (PASI > 10, n = 23). Notably, IL-17C and PI3 were decreased with all four examined systemic treatment types. Furthermore, in patients without CVD, we observed strong correlations among IL-17C/PI3/PASI (r ≥ 0.82, p ≤ 1.5 × 10−12) pairs or between IL-17A/PASI (r = 0.72, p = 9.3 × 10−8). In patients with CVD, the IL-17A/PASI correlation was abolished (r = 0.2, p = 0.24) and the other correlations were decreased, e.g., IL-17C/PI3 (r = 0.61, p = 4.5 × 10−5). Patients with moderate-to-severe psoriasis and CVD had lower levels of IL-17A compared to those without CVD (normalized protein expression [NPX] 2.02 vs. 2.55, p = 0.013), and lower IL-17A levels (NPX < 2.3) were associated with higher incidence of CVD (OR = 24.5, p = 0.0028, 95% CI 2.1–1425.1). As a result, in patients with moderate-to-severe psoriasis, we propose circulating IL-17C and PI3 as potential biomarkers of effective systemic anti-psoriatic treatment, and IL-17A as potential marker of CVD.

Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-RISK, descriptive study

2014 ◽  
Vol 24 (6) ◽  
pp. 662-669 ◽  
Author(s):  
Francisco Vanaclocha ◽  
Isabel Belinchón ◽  
José L. Sánchez-Carazo ◽  
Raquel Rivera ◽  
José M. Carrascosa ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Cardiovascular Diseases ◽  
Cardiovascular Risk Factors ◽  
Systemic Treatment ◽  
Descriptive Study ◽  
Severe Psoriasis

scholarly journals Systemic treatment for severe psoriasis in a patient with autoimmune cytopenia

2020 ◽  
Vol 6 (3) ◽  
pp. 224
Author(s):  
Mary Kathryn Abel ◽  
Raagini Suresh ◽  
Jodie Raffi ◽  
Kristin Razzeca ◽  
Jenny E. Murase
Keyword(s):  
Systemic Treatment ◽  
Severe Psoriasis ◽  
Autoimmune Cytopenia

Systemic Treatment of Severe Psoriasis

1991 ◽  
Vol 324 (5) ◽  
pp. 333-334 ◽  
Author(s):  
Nicholas J. Lowe
Keyword(s):  
Systemic Treatment ◽  
Severe Psoriasis

European Society of Gynecological Oncology Task Force for Fertility Preservation: Clinical Recommendations for Fertility-Sparing Management in Young Endometrial Cancer Patients

2015 ◽  
Vol 25 (7) ◽  
pp. 1258-1265 ◽  
Author(s):  
Alexandros Rodolakis ◽  
Ioannis Biliatis ◽  
Philippe Morice ◽  
Nick Reed ◽  
Mandy Mangler ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Task Force ◽  
Survival Rates ◽  
Reproductive Age ◽  
Obstetric Outcomes ◽  
Published Data ◽  
High Dose ◽  
Conservative Approach ◽  
Clinical Recommendations ◽  
Fertility Sparing

AbstractEndometrial cancer (EC) in young women of reproductive age is a relatively rare diagnosis. However, since in the modern era women delay their childbearing for a variety of social reasons, more and more women in the near future will be nulliparous and have a diagnosis of EC at the same time. Hence, a more conservative approach of EC is desirable to preserve fertility of these women, without compromising their survival. Recently, the number of studies reporting encouraging results on fertility-sparing management of EC with high dose of progestins is increasing. It seems that preserving the uterus and the ovaries in a carefully selected patient with EC confers only a very small risk combined with an enormous benefit. Selection of women suitable for such a conservative approach, as well as method of treatment, follow-up, recurrence, obstetric outcomes, and survival rates are very important parameters when consulting women with EC wishing to preserve their fertility. In this article, we try to elucidate all the previously mentioned aspects and formulate clinical recommendations, based on published data, about the most proper approach and consultation of these patients.

scholarly journals Systemic treatment of psoriasis: from methotrexate to biologics

2020 ◽  
Vol 96 (3) ◽  
pp. 7-26
Author(s):  
Olga Yu. Olisova ◽  
Ekaterina M. Anpilogova
Keyword(s):  
Skin Diseases ◽  
Systemic Treatment ◽  
Treatment Options ◽  
Certolizumab Pegol ◽  
Severe Psoriasis ◽  
Unknown Etiology ◽  
Inflammatory Skin Diseases ◽  
New Era ◽  
Complete Clinical Remission

Psoriasis is one of the most frequent chronic inflammatory skin diseases and it has been of interest to many scientists for ages. The review presents data on all systemic treatment options, that are to date officially registered in Russian Federation for moderate-to-severe psoriasis. Aspects of the mechanism of action, efficacy and tolerability of both basic drugs (methotrexate, cyclosporine, acitretin) and biologics (infliximab, adalimumab, etanercept, certolizumab pegol, ustekinumab, guselkumab, secukinumab, ixekizumab, netakimab) and small molecules (tofacitinib, apremilast) are considered in detail. Special emphasis is placed on the important nuances of biological therapy: immunogenicity, drugs' survival and switch due to lack of efficacy. Invention of biologics signified a new era of moderate-to-severe psoriasis treatment. It became possible to achieve complete clinical remission more safely, which significantly improved the quality of life of patients. However, due to the unknown etiology of psoriasis, there is still no universal remedy that would allow to cure every patient, this fact makes scientists from all over the world keep conducting numerous clinical trials to find even more effective and safe therapeutic options.

scholarly journals Draft recommendations of the russian society of pediatric gastroenterology, hepatology and nutrition on diagnosis and treatment of Crohn's disease in children

2019 ◽  
pp. 100-134 ◽  
Author(s):  
E. A. Kornienko ◽  
A. I. Khavkin ◽  
E. N. Fedulova ◽  
G. V. Volynets ◽  
T. V. Gabruskaya ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Diagnosis And Treatment ◽  
Russian Society ◽  
Pediatric Gastroenterology ◽  
Final Approval ◽  
Final Version ◽  
Clinical Recommendations

The final version of the draft protocol for the diagnosis and treatment of Crohn’s disease in children, developed by experts of the Russian Society of Pediatric Gastroenterology, Hepatology and Nutrition, is presented in the article. This project has been repeatedly discussed by pediatric gastroenterologists - specialists in the study of IBD in children during round tables at the XXV-th and XXVI-th Congres of Pediatric Gastroenterologists of Russia and, after final approval, will be presented in the form of clinical recommendations.

Sign in / Sign up

Export Citation Format

Share Document